Walgreens Boots Alliance, Inc. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 31 mei 2024 (2025)

FAQs

What is Walgreens earnings call for 2024? ›

We now expect to deliver adjusted earnings per share of $2.80 to $2.95 for the fiscal-year 2024. While we acknowledge that this range is wider than normal, we believe it is prudent given fluctuations in recent pharmacy industry trends.

THE LAWSUIT: A class action securities lawsuit was filed against Walgreens Boots Alliance, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between October 12, 2023 and June 26, 2024.

Walgreens Boots Alliance, Inc.

(WBA) is an American multinational holding company headquartered in Deerfield, Illinois, which owns the retail pharmacy chains Walgreens in the US and Boots in the UK, as well as several pharmaceutical manufacturing and distribution companies.

Walgreens Boots Alliance has a market cap or net worth of $9.32 billion as of August 20, 2024. Its market cap has decreased by -64.37% in one year.

According to Walgreens Boots Alliance's latest financial reports the company's total debt is $32.67 B. A company's total debt is the sum of all current and non-current debts.

Walgreens Boots Alliance and its predecessor company, Walgreen Co. , have paid a dividend in 366 straight quarters (91 years).

The ownership structure of Walgreens Boots Alliance (WBA) stock is a mix of institutional, retail and individual investors. Approximately 44.24% of the company's stock is owned by Institutional Investors, 20.12% is owned by Insiders and 35.64% is owned by Public Companies and Individual Investors.

Chief Executive Officer, Walgreens Boots Alliance, Inc.

Walgreens is a public corporation, so it is owned by the shareholders. You can look up the management, CEO, CFO, COO, and all those other details on the web. It was started in 1901 by “pop” Walgreen and grew from there. The “Waltons” were not involved.

WBA employs more than 331,000 people and has a presence in eight countries through its portfolio of consumer brands: Walgreens, Boots, Duane Reade, the No7 Beauty Company and Benavides in Mexico.

Is Walgreens Boots Alliance a good buy? ›

The average price target represents 16.84% Increase from the current price of $11.7. What do analysts say about Walgreens Boots Alliance? Walgreens Boots Alliance's analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

Walgreens Boots Alliance WBA is a Zacks Rank #5 (Strong Sell), indicating that analysts have taken a bearish stance on the company's earnings outlook.

Stefano Pessina (born 4 June 1941) is an Italian-Monegasque billionaire businessman; he is the executive chairman and largest single shareholder of Walgreens Boots Alliance.

Rosalind Brewer, CEO of Walgreens Boots Alliance, is No. 14 on nonprofit shareholder advocacy group As You Sow's list of "overpaid" healthcare CEOs. The company reported Ms. Brewer's compensation at $28.33 million as of June 30, 2022.

In 2023, the company registered net sales of approximately 139 billion U.S. dollars through its several businesses. That said, most Walgreens Boots Alliance sales are attributed to retail and pharmacy sales in the United States, where Walgreens' retail pharmacies reached 82 billion U.S. dollars in net sales in 2023.

WBA Stock Forecast FAQ

Based on analyst ratings, Walgreens Boots Alliance's 12-month average price target is $13.67. What is WBA's upside potential, based on the analysts' average price target? Walgreens Boots Alliance has 16.84% upside potential, based on the analysts' average price target.

Walgreens recently announced that it plans to eliminate bonuses for corporate staff and reduce bonuses for pharmacy and store managers this year, citing weaker-than-expected financial results.

The company also reported a net income of $344 million, up from $118 million during the same period in 2023. Walgreens' revenue and profitability numbers may be better than they were a year ago, but there are strong headwinds in the U.S. pharmacy world.

Walgreens plans to close a “significant portion” of underperforming stores and lower its stake in primary care provider VillageMD, a shift away from the pharmacy chain's previous strategy to transform into a “consumer-centric” healthcare company.